| HOME >> BIOLOGY >> TECHNOLOGY |
NEW YORK, Feb. 12 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY) today announced that the company's Board of Directors has elected James M. Cornelius chairman of the Board. Mr. Cornelius, who was named chief executive officer in September 2006, will continue serving in that role as well. Mr. Cornelius' current employment contract, which expires in May 2009, will be terminated. The Board also named Lewis B. Campbell, chairman, president and CEO, Textron Inc., as lead independent director. James D. Robinson III, co-founder and general partner, RRE Ventures, resigned as non- executive chairman of the Board, a position he has held since June 2005. He will remain a director of the company until May 6, 2008, the date of the company's Annual Meeting of Stockholders, when he will retire pursuant to the Board's mandatory age retirement policy.
"Speaking for the entire Board, we're delighted that Jim Cornelius will be our next chairman at a critical time when Bristol-Myers Squibb is undergoing a fundamental transformation to a next generation BioPharma company," said Mr. Robinson. "Under Jim's leadership, Bristol-Myers Squibb has been put back on the path of growth, greater profitability and a renewed focus on helping patients prevail over serious diseases. We're confident that as chairman, he and his outstanding leadership team will succeed in their goal of making this a dynamic BioPharma company for the future."
Mr. Cornelius was named CEO of Bristol-Myers Squibb on April 30, 2007, after serving as interim CEO since September 12, 2006. He joined the Board in January 2005.
"I am excited by this tremendous opportunity to serve as chairman of
the Board of this great company," said Mr. Cornelius. "Over the past
'/>"/>
| SOURCE Bristol-Myers Squibb Company Copyright©2008 PR Newswire. All rights reserved |